{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:33:58Z","timestamp":1774924438504,"version":"3.50.1"},"reference-count":25,"publisher":"American Veterinary Medical Association (AVMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To determine the myelosuppressive effects\/hematological toxicities, other general toxicities, and when these occur during vinblastine\/prednisolone chemotherapy in dogs bearing high-grade or metastatic cutaneous\/subcutaneous mast cell tumors (MCTs).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>METHODS<\/jats:title>\n<jats:p>Medical records were retrospectively reviewed between November 1, 2016, and March 1, 2023. Thirty client-owned dogs with histopathologically confirmed cutaneous high-grade MCTs\/metastatic subcutaneous MCTs and that subsequently completed a 12-week vinblastine\/prednisolone chemotherapy protocol were included. Hematology was assessed before commencing chemotherapy and before each vinblastine treatment. The effect of each treatment upon hematological values was evaluated. Measured outcomes included the type, frequency, and severity of hematological and other more general toxicities.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>24 of 30 dogs experienced at least 1 hematological toxicity, 6 experienced gastrointestinal toxicity, and 4 experienced lethargy. The most common toxicity was anemia (15\/30 [50%]), with 93.3% (14\/15 dogs) classified as Veterinary Cooperative Oncology Group\u2013Common Terminology Criteria for Adverse Events grade I and 6.6% (1\/15) classified as grade II. The second most common toxicity was neutropenia (14\/30 [46.6%]), with 71.4% (10\/14) classified as grade I and 28.6% (4\/14) as grade III. The least common hematological toxicity was thrombocytopenia (4\/30 [13%]), all grade I. Neutropenia mainly occurred during weeks 2 and 3; however, there was no significant decrease in neutrophil count relative to baseline. Neutrophil count increased and Hct decreased during weeks 6 to 12 of treatment when compared to baseline. No change in platelet count was observed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CLINICAL RELEVANCE<\/jats:title>\n<jats:p>Vinblastine\/prednisolone chemotherapy leads to hematological toxicity; however, this was mostly low-grade and did not require major intervention. Vinblastine\/prednisolone chemotherapy is well tolerated in dogs bearing high-grade or metastatic MCTs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.24.03.0214","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T14:30:08Z","timestamp":1718980208000},"page":"1644-1649","source":"Crossref","is-referenced-by-count":2,"title":["Vinblastine\/prednisolone chemotherapy leads to hematological toxicity in dogs with high-grade or metastatic mast cell tumors"],"prefix":"10.2460","volume":"262","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6245-7960","authenticated-orcid":true,"given":"Ryan W.","family":"Soussa","sequence":"first","affiliation":[{"name":"Queen\u2019s Veterinary School Hospital, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzie","family":"Jaderberg","sequence":"additional","affiliation":[{"name":"Queen\u2019s Veterinary School Hospital, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim L.","family":"Williams","sequence":"additional","affiliation":[{"name":"Queen\u2019s Veterinary School Hospital, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane M.","family":"Dobson","sequence":"additional","affiliation":[{"name":"Queen\u2019s Veterinary School Hospital, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"issue":"9","key":"ref1","series-title":"Mod Vet Pract","first-page":"766","article-title":"Treatment of a mast cell tumor in a dog","volume":"58","author":"Crow SE","year":"1977","unstructured":"Crow SE. Treatment of a mast cell tumor in a dog. Mod Vet Pract. 1977;58(9):766-767."},{"issue":"2","key":"ref2","series-title":"J Am Anim Hosp Assoc","first-page":"124","article-title":"Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors","volume":"40","author":"Davies DR","year":"2004","unstructured":"Davies DR, Wyatt KM, Jardine JE, Robertson ID, Irwin PJ. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc. 2004;40(2):124-130. doi:10.5326\/0400124"},{"issue":"6","key":"ref3","series-title":"J Vet Intern Med","first-page":"1390","article-title":"Efficacy of vinblastine for treatment of canine mast cell tumors","volume":"22","author":"Rassnick KM","year":"2008","unstructured":"Rassnick KM, Bailey DB, Flory AB,  Efficacy of vinblastine for treatment of canine mast cell tumors. J Vet Intern Med. 2008;22(6):1390-1396. doi:10.1111\/j.1939-1676.2008.0195.x"},{"issue":"5","key":"ref4","series-title":"J Vet Intern Med","first-page":"491","article-title":"Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997)","volume":"13","author":"Thamm DH","year":"1999","unstructured":"Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). J Vet Intern Med. 1999;13(5):491-497. doi:10.1892\/0891-6640(1999)013<0491:pavcfc>2.3.co;2"},{"issue":"6","key":"ref5","series-title":"J Vet Med Sci","first-page":"581","article-title":"Outcome and prognostic factors following adjuvant prednisone\/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases","volume":"68","author":"Thamm DH","year":"2006","unstructured":"Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone\/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci. 2006;68(6):581-587. doi:10.1292\/jvms.68.581"},{"issue":"6","key":"ref6","series-title":"J Vet Med A Physiol Pathol Clin Med","first-page":"275","article-title":"Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours","volume":"52","author":"Trumel C","year":"2005","unstructured":"Trumel C, Bourg\u00e8s-Abella N, Touron C,  Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours. J Vet Med A Physiol Pathol Clin Med. 2005;52(6):275-279. doi:10.1111\/j.1439-0442.2005.00725.x"},{"issue":"2","key":"ref7","series-title":"Vet Comp Oncol","first-page":"111","article-title":"Dose-escalating vinblastine for the treatment of canine mast cell tumour","volume":"6","author":"Vickery KR","year":"2008","unstructured":"Vickery KR, Wilson H, Vail DM, Thamm DH. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Vet Comp Oncol. 2008;6(2):111-119. doi:10.1111\/j.1476-5829.2007.00147.x"},{"issue":"3","key":"ref8","series-title":"Vet Comp Oncol","first-page":"168","article-title":"Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours","volume":"5","author":"Hayes A","year":"2007","unstructured":"Hayes A, Adams V, Smith K, Maglennon G, Murphy S. Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. Vet Comp Oncol. 2007;5(3):168-176. doi:10.1111\/j.1476-5829.2007.00135.x"},{"issue":"9","key":"ref9","series-title":"J Am Vet Med Assoc","first-page":"1114","article-title":"Uses of vincristine and vinblastine in dogs and cats","volume":"193","author":"Golden DL","year":"1988","unstructured":"Golden DL, Langston VC. Uses of vincristine and vinblastine in dogs and cats. J Am Vet Med Assoc. 1988;193(9):1114-1117."},{"key":"ref10","series-title":"Cancer Chemotherapy and Biotherapy Principles and Practice","first-page":"216","article-title":"Antimitotic drugs","author":"Rowinsky KE","year":"2011","unstructured":"Rowinsky KE. Antimitotic drugs. In: Cancer Chemotherapy and Biotherapy Principles and Practice. 5th ed. Lippincott Williams and Wilkins; 2011:216-266."},{"issue":"5","key":"ref11","series-title":"Cancer Res","first-page":"1116","article-title":"Pharmacological studies with vinblastine in the dog","volume":"35","author":"Creasey WA","year":"1975","unstructured":"Creasey WA, Scott AI, Wei CC, Kutcher J, Schwartz A, Marsh JC. Pharmacological studies with vinblastine in the dog. Cancer Res. 1975;35(5):1116-1120."},{"issue":"2","key":"ref12","series-title":"Vet Comp Oncol","first-page":"311","article-title":"Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"LeBlanc AK","year":"2021","unstructured":"LeBlanc AK, Atherton M, Bentley RT,  Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021;19(2):311-352. doi:10.1111\/vco.12677"},{"issue":"9","key":"ref13","series-title":"J Small Anim Pract","first-page":"534","article-title":"Haematologic toxicity in dogs with mast cell tumours treated with vinblastine\/prednisolone chemotherapy with\/without radiotherapy","volume":"60","author":"Stiborova K","year":"2019","unstructured":"Stiborova K, Treggiari E, Amores-Fuster I,  Haematologic toxicity in dogs with mast cell tumours treated with vinblastine\/prednisolone chemotherapy with\/without radiotherapy. J Small Anim Pract. 2019;60(9):534-542. doi:10.1111\/jsap.13047"},{"issue":"4","key":"ref14","series-title":"J Comp Pathol","first-page":"329","article-title":"Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis","volume":"151","author":"Weishaar KM","year":"2014","unstructured":"Weishaar KM, Thamm DH, Worley DR, Kamstock DA. Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis. J Comp Pathol. 2014;151(4):329-338. doi:10.1016\/j.jcpa.2014.07.004"},{"issue":"7","key":"ref15","series-title":"J Small Anim Pract","first-page":"348","article-title":"A review of anaemia of inflammatory disease in dogs and cats","volume":"57","author":"Chikazawa S","year":"2016","unstructured":"Chikazawa S, Dunning MD. A review of anaemia of inflammatory disease in dogs and cats. J Small Anim Pract. 2016;57(7):348-353. doi:10.1111\/jsap.12498"},{"issue":"3","key":"ref16","series-title":"Vet Comp Oncol","first-page":"174","article-title":"Safety evaluation of combination vinblastine and toceranib phosphate (Palladia\u00ae) in dogs: a phase I dose-finding study","volume":"10","author":"Robat C","year":"2012","unstructured":"Robat C, London C, Bunting L,  Safety evaluation of combination vinblastine and toceranib phosphate (Palladia\u00ae) in dogs: a phase I dose-finding study. Vet Comp Oncol. 2012;10(3):174-183. doi:10.1111\/j.1476-5829.2011.00261.x"},{"issue":"2","key":"ref17","series-title":"Vet Pathol","first-page":"298","article-title":"Nonregenerative anemia: mechanisms of decreased or ineffective erythropoiesis","volume":"52","author":"Grimes CN","year":"2015","unstructured":"Grimes CN, Fry MM. Nonregenerative anemia: mechanisms of decreased or ineffective erythropoiesis. Vet Pathol. 2015;52(2):298-311. doi:10.1177\/0300985814529315"},{"issue":"3","key":"ref18","series-title":"Top Companion Anim Med","first-page":"122","article-title":"Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity","volume":"24","author":"Vail DM","year":"2009","unstructured":"Vail DM. Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity. Top Companion Anim Med. 2009;24(3):122-129. doi:10.1053\/j.tcam.2009.02.004"},{"issue":"1","key":"ref19","series-title":"Blood","first-page":"53","article-title":"Leukokinetics studies. VII. Morphology of the bone marrow and blood of dogs given vinblastine sulphate","volume":"23","author":"Boggs DR","year":"1964","unstructured":"Boggs DR, Athens JW, Haab OP,  Leukokinetics studies. VII. Morphology of the bone marrow and blood of dogs given vinblastine sulphate. Blood. 1964;23(1):53-67. doi:10.1182\/blood.V23.1.53.53"},{"issue":"4","key":"ref20","series-title":"Vet Med Sci","first-page":"266","article-title":"Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours","volume":"2","author":"Serra Varela JC","year":"2016","unstructured":"Serra Varela JC, Pecceu E, Handel I, Lawrence J. Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours. Vet Med Sci. 2016;2(4):266-280. doi:10.1002\/vms3.42"},{"issue":"6","key":"ref21","series-title":"J Vet Intern Med","first-page":"1332","article-title":"Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol","volume":"21","author":"Vaughan A","year":"2007","unstructured":"Vaughan A, Johnson JL, Williams LE. Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. J Vet Intern Med. 2007;21(6):1332-1339. doi:10.1892\/06-197.1"},{"issue":"3","key":"ref22","series-title":"Nat Clin Pract Oncol","first-page":"153","article-title":"Pharmacogenomic progress in individualized dosing of key drugs for cancer patients","volume":"6","author":"Walko CM","year":"2009","unstructured":"Walko CM, McLeod H. Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol. 2009;6(3):153-162. doi:10.1038\/ncponc1303"},{"issue":"3","key":"ref23","series-title":"Aust Vet J","first-page":"79","article-title":"Breed is associated with the ABCB1-1\u0394 mutation in Australian dogs","volume":"98","author":"Soussa RW","year":"2020","unstructured":"Soussa RW, Woodward A, Marty M, Cannon CM. Breed is associated with the ABCB1-1\u0394 mutation in Australian dogs. Aust Vet J. 2020;98(3):79-83. doi:10.1111\/avj.12896"},{"issue":"4","key":"ref24","series-title":"J Vet Intern Med","first-page":"996","article-title":"ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine","volume":"22","author":"Mealey KL","year":"2008","unstructured":"Mealey KL, Fidel J, Gay JM, Impellizeri JA, Clifford CA, Bergman PJ. ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine. J Vet Intern Med. 2008;22(4):996-1000. doi:10.1111\/j.1939-1676.2008.0122.x"},{"issue":"1","key":"ref25","series-title":"J Vet Intern Med","first-page":"1","article-title":"P-glycoprotein mediated drug interactions in animals and humans with cancer","volume":"29","author":"Mealey KL","year":"2015","unstructured":"Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med. 2015;29(1):1-6. doi:10.1111\/jvim.12525"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/12\/javma.24.03.0214.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/12\/javma.24.03.0214.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/262\/12\/javma.24.03.0214.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T16:21:29Z","timestamp":1741364489000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/262\/12\/javma.24.03.0214.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":25,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.2460\/javma.24.03.0214","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}